[{"id":"c9892233-0e72-4b03-a1a6-ddcbeb8d59bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03289962","created_at":"2021-01-18T16:15:14.579Z","updated_at":"2024-07-02T16:35:07.331Z","phase":"Phase 1","brief_title":"A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors","source_id_and_acronym":"NCT03289962","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • autogene cevumeran (RG6180)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 272","initiation":"Initiation: 12/21/2017","start_date":" 12/21/2017","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2024-04-26"}]